罗氏83亿收购美国制药公司InterMune

2014-08-29 17:33:53来源：可可英语

　　“We are obviously focused on high unmet medical needs and looking for medicines that make asignificant difference clinically, and this clearly fits that bill,” Daniel O’Day, who runs Roche’spharmaceutical business, said in an interview on Sunday.

　　“我们明确地专注于目前无法被满足的重大药品需求，寻找临床上能产生重大影响的药物，而它显然符合我们的要求，”罗氏公司制药业务负责人丹尼尔·奥黛(Daniel O’Day)周日接受采访时说。

　　He said the acquisition would strengthen its portfolio of drugs for respiratory diseases.That has not been a major business for a company mainly known for its cancer treatments.Roche sells Xolair, a drug for asthma, and Pulmozyme for cystic fibrosis. But it has anotherdrug, lebrikizumab, that is in late-stage clinical trials to treat severe asthma and is also beingevaluated as a possible treatment for idiopathic pulmonary fibrosis.

　　他说，这笔交易将强化公司的呼吸系统药物的产品线。罗氏公司以生产抗癌药物闻名，呼吸系统药物并非其主要业务。该公司已推出了治疗哮喘的奥马珠单抗，以及治疗囊肿性纤维化的阿法链道酶。该公司另一款针对严重哮喘的药物lebrikizumab目前处于临床试验的后期，同时正在就其作为特发性肺纤维化药品的可能性接受评估。

　　Roche, however, has historically not relied much on acquisitions for its pharmaceutical business,though it has in its diagnostics business. The big exception was its acquisition of the part ofbiotechnology pioneer Genentech that it did not already own for $46.8 billion in 2009.

　　与该公司的疾病诊断业务不同，罗氏的制药业务长期以来并没有过多地依赖收购交易。不过，一个较大的例外情况是，该公司在2009年曾以468亿美元的价格收购不在其手中的生物科技先锋企业基因泰克(Genentech)的部分股份。

　　In the last couple of months, Roche has announced some smaller acquisitions, agreeing to payat least $725 million for privately held Seragon Pharmaceuticals, which is developing breastcancer drugs, and at least $250 million for privately held Santaris Pharma, which develops drugsthat work by affecting RNA.

　　过去几个月，罗氏宣布了几笔规模较小的收购交易，包括以至少7.25亿美元收购私人持股的SeragonPharmaceuticals，以及以至少2.5亿美元收购了私人持股的Santaris Pharma。Seragon Pharmaceuticals正在开发乳腺癌药物。而Santaris Pharma开发的药物主要通过影响RNA产生疗效。

　　Idiopathic pulmonary fibrosis, which has no known cause, affects 70,000 to 200,000 Americans,according to various estimates. As scarring builds up in the lungs, people gradually lose theability to breathe. Death often occurs two to five years after diagnosis.

　　特发性肺纤维化的原因尚不明确，各类数据显示，美国的患病人数在7万到20万之间。随着肺部结痂的增多，患者会逐渐丧失呼吸能力，且通常在确诊后两至五年内死亡。

　　No treatments are approved for use in the United States, though steroids and some otherdrugs are used off label, and a relatively small number of patients can receive lung transplants.

　　美国没有批准任何特发性肺纤维化的治疗方法，但是类固醇等药物已通过超适应症用药投入使用，少数患者可以接受肺部移植手术。

　　But Esbriet, if it is approved, probably will not have the market to itself for long becauseBoehringer Ingelheim of Germany has also applied for approval of a drug called nintedanib.

　　不过，Esbriet即使获批，可能也无法长期垄断市场，这是因为德国制药企业勃林格殷格翰(BoehringerIngelheim)正在申请批准的一款名为nintedanib的药物。

　　Both drugs slow the decline in lung function, according to papers in The New England Journalof Medicine in May. Evidence from clinical trials indicates that pirfenidone can also help patientslive longer, though it is not clear if the evidence is strong enough for that to be listed on thedrug’s label if it is approved.

　　这两种药物都能够延缓肺功能衰竭的速度，《新英格兰医学杂志》(The New England Journal ofMedicine)5月发表的一篇论文称。临床试验得到的证据显示，吡非尼酮也能延长患者的寿命，不过尚不清楚相关证据是否足够强大，让这一点可以在药品获批后出现在标签上。

　　Mr. O’Day said data from the latest clinical trial, published in May, drew Roche’s interest. Hesaid his company approached InterMune in late July.

　　奥黛说，5月发表的最新临床试验数据吸引了罗氏公司。他说，罗氏公司在7月末接触了InterMune。

本文关键字: 罗氏83亿收购美国制药公司